Laparoscopic fundoplication compared with medical management for gastro-oesophageal reflux disease: cost effectiveness study

David Epstein, Laura Bojke, Mark J Sculpher, Marion K Campbell (Collaborator), REFLUX Trial Group

Research output: Contribution to journalArticle

30 Citations (Scopus)
3 Downloads (Pure)

Abstract

OBJECTIVE: To describe the long term costs, health benefits, and cost effectiveness of laparoscopic surgery compared with those of continued medical management for patients with gastro-oesophageal reflux disease (GORD). DESIGN: We estimated resource use and costs for the first year on the basis of data from the REFLUX trial. A Markov model was used to extrapolate cost and health benefit over a lifetime using data collected in the REFLUX trial and other sources. PARTICIPANTS: The model compared laparoscopic surgery and continued proton pump inhibitors in male patients aged 45 and stable on GORD medication. INTERVENTION: Laparoscopic surgery versus continued medical management. MAIN OUTCOME MEASURES: We estimated quality adjusted life years and GORD related costs to the health service over a lifetime. Sensitivity analyses considered other plausible scenarios, in particular size and duration of treatment effect and the GORD symptoms of patients in whom surgery is unsuccessful. Main results The base case model indicated that surgery is likely to be considered cost effective on average with an incremental cost effectiveness ratio of pound2648 (euro3110; US$4385) per quality adjusted life year and that the probability that surgery is cost effective is 0.94 at a threshold incremental cost effectiveness ratio of pound20 000. The results were sensitive to some assumptions within the extrapolation modelling. CONCLUSION: Surgery seems to be more cost effective on average than medical management in many of the scenarios examined in this study. Surgery might not be cost effective if the treatment effect does not persist over the long term, if patients who return to medical management have poor health related quality of life, or if proton pump inhibitors were cheaper. Further follow-up of patients from the REFLUX trial may be valuable. TRIAL REGISTRATION: ISRCTN15517081.
Original languageEnglish
Article numberb2576
Number of pages7
JournalBritish Medical Journal
Volume339
DOIs
Publication statusPublished - 14 Jul 2009

Fingerprint

Esophageal Diseases
Fundoplication
Cost of Illness
Gastroesophageal Reflux
Cost-Benefit Analysis
Laparoscopy
Costs and Cost Analysis
Quality-Adjusted Life Years
Proton Pump Inhibitors
Insurance Benefits
Health Care Costs
Health Services
Quality of Life

Keywords

  • age distribution
  • aged
  • aged, 80 and over
  • cost-benefit analysis
  • fundoplication
  • gastroesophageal reflux
  • health resources
  • humans
  • laparoscopy
  • male
  • Markov chains
  • middle aged
  • proton pump inhibitors
  • quality of life
  • quality-adjusted life years

Cite this

Laparoscopic fundoplication compared with medical management for gastro-oesophageal reflux disease : cost effectiveness study. / Epstein, David; Bojke, Laura; Sculpher, Mark J; Campbell, Marion K (Collaborator); REFLUX Trial Group.

In: British Medical Journal, Vol. 339, b2576, 14.07.2009.

Research output: Contribution to journalArticle

@article{e096bbc0b9ab417a8dd64ef29e90b864,
title = "Laparoscopic fundoplication compared with medical management for gastro-oesophageal reflux disease: cost effectiveness study",
abstract = "OBJECTIVE: To describe the long term costs, health benefits, and cost effectiveness of laparoscopic surgery compared with those of continued medical management for patients with gastro-oesophageal reflux disease (GORD). DESIGN: We estimated resource use and costs for the first year on the basis of data from the REFLUX trial. A Markov model was used to extrapolate cost and health benefit over a lifetime using data collected in the REFLUX trial and other sources. PARTICIPANTS: The model compared laparoscopic surgery and continued proton pump inhibitors in male patients aged 45 and stable on GORD medication. INTERVENTION: Laparoscopic surgery versus continued medical management. MAIN OUTCOME MEASURES: We estimated quality adjusted life years and GORD related costs to the health service over a lifetime. Sensitivity analyses considered other plausible scenarios, in particular size and duration of treatment effect and the GORD symptoms of patients in whom surgery is unsuccessful. Main results The base case model indicated that surgery is likely to be considered cost effective on average with an incremental cost effectiveness ratio of pound2648 (euro3110; US$4385) per quality adjusted life year and that the probability that surgery is cost effective is 0.94 at a threshold incremental cost effectiveness ratio of pound20 000. The results were sensitive to some assumptions within the extrapolation modelling. CONCLUSION: Surgery seems to be more cost effective on average than medical management in many of the scenarios examined in this study. Surgery might not be cost effective if the treatment effect does not persist over the long term, if patients who return to medical management have poor health related quality of life, or if proton pump inhibitors were cheaper. Further follow-up of patients from the REFLUX trial may be valuable. TRIAL REGISTRATION: ISRCTN15517081.",
keywords = "age distribution, aged, aged, 80 and over, cost-benefit analysis, fundoplication, gastroesophageal reflux, health resources, humans, laparoscopy, male, Markov chains, middle aged, proton pump inhibitors, quality of life , quality-adjusted life years",
author = "David Epstein and Laura Bojke and Sculpher, {Mark J} and Campbell, {Marion K} and {REFLUX Trial Group}",
year = "2009",
month = "7",
day = "14",
doi = "10.1136/bmj.b2576",
language = "English",
volume = "339",
journal = "BMJ",
issn = "0959-8146",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Laparoscopic fundoplication compared with medical management for gastro-oesophageal reflux disease

T2 - cost effectiveness study

AU - Epstein, David

AU - Bojke, Laura

AU - Sculpher, Mark J

AU - REFLUX Trial Group

A2 - Campbell, Marion K

PY - 2009/7/14

Y1 - 2009/7/14

N2 - OBJECTIVE: To describe the long term costs, health benefits, and cost effectiveness of laparoscopic surgery compared with those of continued medical management for patients with gastro-oesophageal reflux disease (GORD). DESIGN: We estimated resource use and costs for the first year on the basis of data from the REFLUX trial. A Markov model was used to extrapolate cost and health benefit over a lifetime using data collected in the REFLUX trial and other sources. PARTICIPANTS: The model compared laparoscopic surgery and continued proton pump inhibitors in male patients aged 45 and stable on GORD medication. INTERVENTION: Laparoscopic surgery versus continued medical management. MAIN OUTCOME MEASURES: We estimated quality adjusted life years and GORD related costs to the health service over a lifetime. Sensitivity analyses considered other plausible scenarios, in particular size and duration of treatment effect and the GORD symptoms of patients in whom surgery is unsuccessful. Main results The base case model indicated that surgery is likely to be considered cost effective on average with an incremental cost effectiveness ratio of pound2648 (euro3110; US$4385) per quality adjusted life year and that the probability that surgery is cost effective is 0.94 at a threshold incremental cost effectiveness ratio of pound20 000. The results were sensitive to some assumptions within the extrapolation modelling. CONCLUSION: Surgery seems to be more cost effective on average than medical management in many of the scenarios examined in this study. Surgery might not be cost effective if the treatment effect does not persist over the long term, if patients who return to medical management have poor health related quality of life, or if proton pump inhibitors were cheaper. Further follow-up of patients from the REFLUX trial may be valuable. TRIAL REGISTRATION: ISRCTN15517081.

AB - OBJECTIVE: To describe the long term costs, health benefits, and cost effectiveness of laparoscopic surgery compared with those of continued medical management for patients with gastro-oesophageal reflux disease (GORD). DESIGN: We estimated resource use and costs for the first year on the basis of data from the REFLUX trial. A Markov model was used to extrapolate cost and health benefit over a lifetime using data collected in the REFLUX trial and other sources. PARTICIPANTS: The model compared laparoscopic surgery and continued proton pump inhibitors in male patients aged 45 and stable on GORD medication. INTERVENTION: Laparoscopic surgery versus continued medical management. MAIN OUTCOME MEASURES: We estimated quality adjusted life years and GORD related costs to the health service over a lifetime. Sensitivity analyses considered other plausible scenarios, in particular size and duration of treatment effect and the GORD symptoms of patients in whom surgery is unsuccessful. Main results The base case model indicated that surgery is likely to be considered cost effective on average with an incremental cost effectiveness ratio of pound2648 (euro3110; US$4385) per quality adjusted life year and that the probability that surgery is cost effective is 0.94 at a threshold incremental cost effectiveness ratio of pound20 000. The results were sensitive to some assumptions within the extrapolation modelling. CONCLUSION: Surgery seems to be more cost effective on average than medical management in many of the scenarios examined in this study. Surgery might not be cost effective if the treatment effect does not persist over the long term, if patients who return to medical management have poor health related quality of life, or if proton pump inhibitors were cheaper. Further follow-up of patients from the REFLUX trial may be valuable. TRIAL REGISTRATION: ISRCTN15517081.

KW - age distribution

KW - aged

KW - aged, 80 and over

KW - cost-benefit analysis

KW - fundoplication

KW - gastroesophageal reflux

KW - health resources

KW - humans

KW - laparoscopy

KW - male

KW - Markov chains

KW - middle aged

KW - proton pump inhibitors

KW - quality of life

KW - quality-adjusted life years

U2 - 10.1136/bmj.b2576

DO - 10.1136/bmj.b2576

M3 - Article

C2 - 19654097

VL - 339

JO - BMJ

JF - BMJ

SN - 0959-8146

M1 - b2576

ER -